Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02534844|
Recruitment Status : Recruiting
First Posted : August 28, 2015
Last Update Posted : November 7, 2018
|Condition or disease||Intervention/treatment||Phase|
|Niemann-Pick Disease, Type C||Drug: VTS-270 Drug: Sham Procedure Control||Phase 2 Phase 3|
Non-clinical studies and a Phase 1 clinical trial suggest that intrathecal administration of 2-hydroxypropyl- β-cyclodextrin (VTS-270) in patients with neurologic manifestations of Niemann-Pick Type C1 (NPC1) disease has the potential to slow the rate of progression of their neurologic disease.
Niemann-Pick Type C1 (NPC1) disease is a rare, neurodegenerative, inherited, autosomal recessive lysosomal lipid storage disorder primarily in children and teenagers. The disease is characterized by the inability to properly metabolize cholesterol and other lipids within the cell due to mutations in the NPC1 gene causing unesterified cholesterol to accumulate in the brain, liver and spleen.
This study is a multicenter, multinational, prospective, randomized, double-blind, sham-controlled, 3-part, efficacy and safety trial of VTS-270, administered by the lumbar intrathecal route (IT) every 2 weeks, with a planned enrollment of approximately 51 subjects with NPC1 disease. The study will be conducted in three parts: Parts A, B, and C.
Part A will evaluate 3 different dose levels of VTS-270 in 9 subjects and 3 sham control subjects to determine the dose level for Parts B and C.
Part B will evaluate the safety and efficacy of the dose selected from Part A compared to sham control in 51 subjects, including the 12 subjects from Part A.
Part C will be an open-label extension phase of the study to subjects who either complete Part B or are subjects in Part B who have met rescue therapy criteria.
Subjects in Part C will receive treatment with VTS-270 until the product is licensed or the program is terminated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||51 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease|
|Actual Study Start Date :||October 2015|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Part A: Three (3) different VTS-270 lumbar intrathecal doses (900 mg, 1200 mg, and 1800 mg) administered IT every 2 weeks for 8 weeks in 9 subjects; 3 subjects will receive sham treatment. Dose for Part B to be selected for the remainder of the study.
Part B: Approximately 51 subjects, including 12 from Part A, will receive lumbar intrathecal infusions of VTS-270 or sham (randomized 2:1) every 2 weeks for a total of 52 weeks.
Part C: Open-label extension with IT treatment every 2 weeks.
Lumber intrathecal infusion of VTS-270 (dose to be selected after Part A)
Sham Comparator: Sham Procedure Control
Sixteen (16) subjects, including 3 from Part A.
Drug: Sham Procedure Control
No experimental drug administered to patients. All intrathecal administrations are simulated.
Other Name: Sham group
- NPC Clinical Severity Score [ Time Frame: 52 weeks ]Data for NPC score rating will be provided to a centralized independent blinded rater who will analyze all NPC information for all subjects and assign the NPC Clinical Severity Score.
- Clinician and Caregiver Clinical Global Impression of Change [ Time Frame: 52 weeks ]The CGIC will be evaluated using a 7-point Likert scale.
- Time to get up and go test [ Time Frame: 52 weeks ]
- 9-hole peg test [ Time Frame: 52 weeks ]
- Percentage of patients with clinical worsening [ Time Frame: from week 26 through week 52 based on first dose being week 1 ]
- European Quality of Life-5 Dimensions Quality of Life Rating (EQ-5D QoL) [ Time Frame: 52 weeks ]
- Cerebrospinal fluid (CSF) biomarkers [ Time Frame: 52 weeks ]CSF will be collected from subjects receiving study drug and will be stored for possible biomarker analysis.
- Plasma protein biomarkers [ Time Frame: 52 weeks ]Plasma samples will be collected and stored for possible biomarker analysis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02534844
|Contact: Susan VanMeter, MDfirstname.lastname@example.org|
|Contact: Karrie Hilsinger, B.S.||908-238-6448||Karrie.email@example.com|
|United States, California|
|Children's Hospital of Orange County||Recruiting|
|Orange, California, United States, 92868|
|Contact: Raymond Wang, MD 714-509-8852 firstname.lastname@example.org|
|Contact: Nina Movsesyan 1-714-509-3008 email@example.com|
|University of California San Francisco||Recruiting|
|San Francisco, California, United States, 94143|
|Contact: Renata Gallagher, MD 415-476-3572 firstname.lastname@example.org|
|Contact: Nora Darago 1-415-476-6997 email@example.com|
|United States, Illinois|
|Rush University Medical Center||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Elizabeth Berry-Kravis, MD PhD 312-942-4036 Elizabeth_Berry-Kravis@rush.edu|
|Contact: Jamie A Chin 1-312-942-4036 Jamie_A_Chin@rush.edu|
|United States, Maryland|
|National Institute of Child Health and Human Development at NIH||Recruiting|
|Bethesda, Maryland, United States, 20878|
|Contact: Forbes D Porter, M.D., Ph.D. 301-435-4432 firstname.lastname@example.org|
|Contact: Nicole Farhat, NP 301-594-1765 email@example.com|
|United States, Massachusetts|
|Boston Children's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Olaf Bodamer, MD, PhD, FAAP, FACMG 1 857-218-5544 firstname.lastname@example.org|
|Contact: Sophia Kon 1 617-919-1399 email@example.com|
|United States, New York|
|Montefiore Medical Center||Recruiting|
|Bronx, New York, United States, 10467|
|Contact: Paul Levy, MD 718-741-2323 firstname.lastname@example.org|
|Contact: Jessica Fishetti email@example.com|
|United States, Pennsylvania|
|Lehigh Valley Health Network||Recruiting|
|Allentown, Pennsylvania, United States, 18103|
|Contact: Sameh Morkous, MD 610-402-9543 firstname.lastname@example.org|
|Contact: Sagan Loburak 610-402-8447 sagan_M.Loburak@lvhn.org|
|The Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Can Ficicioglu, MD 215-590-1000 Ficicioglu@email.chop.edu|
|Contact: Alicia Hurnton 1-267-425-2174 HURNTONA@email.chop.edu|
|United States, Texas|
|Dell Children's Medical Center of Central Texas||Recruiting|
|Austin, Texas, United States, 78723|
|Contact: James Gibson, MD 512-628-1840 JBGibson@seton.org|
|Contact: Theresa Viduya, MSN, RN, RNBC 512-324-9999 ext 87081 email@example.com|
|Monash Medical Centre||Recruiting|
|Clayton, Victoria, Australia, 3168|
|Contact: Michael Fahey, A/Prof +61 3 9594 3499 Michael.Fahey@monash.edu|
|Contact: Marie Backstrom +61 9594 1487 firstname.lastname@example.org|
|Royal Melbourne Hospital||Recruiting|
|Parkville, Victoria, Australia, 3050|
|Contact: Mark Walterfang, A/Prof + 61 3 9342 8750 email@example.com|
|Contact: Sean Hosking +61 3 9342 4657 firstname.lastname@example.org|
|CHU Paris Est - Hospital d'Enfants Armand-Trousseau||Recruiting|
|Paris, Cadex 12, France, 75 571|
|Contact: Benedicte Heron, MD (0)1 44 73 66 93 email@example.com|
|Contact: Samira Zebiche (0)1 40 87 52 86 firstname.lastname@example.org|
|Ruhr University, St. Josefs-Hospital||Recruiting|
|Contact: Nesrin Karabul, MD +49 176 551 295 38 email@example.com|
|Contact: Sandra Böger +49 234 509 2809 firstname.lastname@example.org|
|Universitätsmedizin der Johannes Gutenberg-Universität Mainz||Recruiting|
|Contact: Julia Hennermann, Univ. Prof. Dr. med. +49 (0) 6131 17 5754 email@example.com|
|Contact: Petra Kleinhans +49 (0) 6131 17 4579 firstname.lastname@example.org|
|Hospital Universitario del Valle Hebron||Recruiting|
|Barcelona, Spain, 08035|
|Contact: Miereia Del Toro Riera, Dra. +34 93 489 31 56 email@example.com|
|Contact: Carla Aguilar Blancafort +34 93 274 67 20 firstname.lastname@example.org|
|Gazi Universitesi Araştırma ve Uygulama Hastanesi||Recruiting|
|Contact: Fatih Ezgü, Prof. Dr. 00905326853697 email@example.com|
|Contact: Deniz Koca 0090 549 610 12 85 firstname.lastname@example.org|
|Hacettepe Universitesi Hastanesi||Recruiting|
|Contact: Meral Topçu, Prof. Dr. 00905323657282 email@example.com|
|Contact: Yonca Kanal 0090 549 610 12 84 firstname.lastname@example.org|
|Birmingham Children's Hospital||Recruiting|
|Birmingham, United Kingdom, B4 6NH|
|Contact: Suresh Vijay, MD, Consultant IMD 44 (0) 1213339907 email@example.com|
|Contact: Alice Stewart 44 (0) 1213339954 firstname.lastname@example.org|
|Great Ormond Street Hospital||Recruiting|
|London, United Kingdom, WC1N 3JH|
|Contact: Paul Gissen, PhD, MRCPCH +44(0)2078297989 email@example.com|
|Contact: Stephanie Tingley +44(0)2074056892 Stephanie.Tingley@gosh.nhs.uk|